Conferences - Results from #520

Viewing 521-540 of 11745 articles

AUA 2024: National Performance of Lymphadenectomy for Muscle-Invasive Urothelial Cancer and an Exploratory Analysis to Define Optimal Lymph Node Yield Based on Southwest Oncology Group S1011 Trial

AUA 2024: Variation in Prostate Cancer Genomic Subtypes Across Prostate MRI PI-RADS Scores and Race

New Data Validating the First AI-Based Biomarker to Stratify Risk of Metastasis in Radical Prostatectomy Patients with Biochemical Recurrence

AUA 2024: Urological Follow-up of Lynch Syndrome: UTUC Incidence and Mutational Patterns in a Dedicated Outpatient Clinic

AUA 2024: mHSPC: Optimizing Combination Therapy

AUA 2024: Impairment of the Patient’s Health-Related Quality of Life Due to a Orthotopic Neobladder After Radical Cystectomy– Defining an Age-Related Threshold

AUA 2024: Development and Validation of a MMAI-Derived Digital Pathology-Based Biomarker Predicting Metastasis for Radical Prostatectomy Patients with Biochemical Recurrence in NRG/RTOG Trials

AUA 2024: Crossfire: Controversies in Urology: Pre-op 3D Models Help Improve Surgical Outcomes in Renal Cancer Surgery

AUA 2024: Diagnostic Performance of Photodynamic Diagnosis with Oral 5-Aminolevulinic Acid for Bladder and Upper Tract Urothelial Carcinoma: A Single-Center, Retrospective Analysis

AUA 2024: Decipher® Predicts Clinically Significant Upgrading on Final Radical Prostatectomy Pathology

AUA 2024: Association between Enfortumab-Vedotin Related Cutaneous Reaction and Serum Albumin Levels in Patients with Advanced Urothelial Cancer

AUA 2024: Updates in Prevention, Diagnostics and Surgery: PSMA PET updates

AUA 2024: Peripheral Neuropathy and Nerve Electrophysiological Changes with Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma: A Prospective Multicenter Cohort Study

AUA 2024: Radiation Oncology for RCC: Localized Disease, Oligometastatic Disease, and the Future

AUA 2024: Nivolumab plus Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone in Patients with Previously Untreated Unresectable or Metastatic Urothelial Carcinoma: Results of Analyses to Characterize Benefit in Responders from the CheckMate 901 Trial

AUA 2024: Risk Stratification for Adjuvant Therapy with High Risk RCC

AUA 2024: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from JAVELIN Bladder 100 in Subgroups Defined by First-Line Chemotherapy Regimen and Analysis of OS from Start of First-Line Chemotherapy

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

AUA 2024: mCRPC: Key Updates in Radioligand Therapy, PSMA Sensitive Disease

AUA 2024: Whitmore Lecture – Optimizing Outcomes in High-Risk Localized Prostate Cancer – Cure is Possible when Cure is Necessary.

22
23
24
25
26
27
28
29
30
31